Recurrent ventilator-associated pneumonia in severe Covid-19 ARDS patients requiring ECMO support.

ABSTRACT:

Objective

To describe ventilator-associated pneumonia (VAP) recurrence in COVID-19 patients requiring extracorporeal membrane oxygenation (ECMO) support, and to evaluate the impact of antimicrobial treatment duration of the first VAP episode on VAP recurrence.

Methods

Adult patients with COVID-19 severe pneumonia on ECMO admitted between March 2020 and January 2022 were retrospectively included. Primary outcome was incidence of VAP recurrence, and secondary outcome was the impact of duration of antimicrobial treatment on VAP recurrence.

Results

Among the 252 included patients, 226 (90%) developed a first VAP. Sixteen had lung abscess and were excluded, leaving 210 patients. VAP recurrence occurred in 172 patients (82%), with a median (IQR) time from first VAP to recur

SUBMITTER: Collado-Lledo E 

PROVIDER: S-EPMC11045714 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature